E VistaGen Therapeutics: Interesting Prospects

The goal of VistaGen is not to displace people off the antidepressants they are on now. It is taking more of a combination approach where AV-101 can be combined with current antidepressants.

Ketamine Safety

VistaGen has been able to modify its AV-101 drug to act like Ketamine, but with none of the adverse side effects associated with it. That’s because Ketamine blocks ion channel activity. On the other hand, AV-101 does not block NMDA ion receptor channel activity, it inhibits it. That leads to no severe side effects for AV-101, neither like ketamine has, nor like the“black box” metabolic effects of standard antidepressants and antipsychotics.

Safety In Neuropathc Pain

VistaGen has shown AV-101 to be a safe and effective drug. The Scandinavian Journal Of Pain, a peer-review  journal, published a study showing AV-101 having an excellent safety profile in neuropathic pain. There were two phase 1 studies that were performed to show the safety and efficacy of AV-101 in neuropathic pain. One phase 1 study was a single dose study, and the second phase 1 study was a multidose. The good news is that both of these phase 1 trials showed that AV-101 was very safe and well tolerated in all patients. In addition, there were no meaningful differences in adverse events between AV-101 and placebo. This safety profile is important because it accomplishes two things. First, it gives future hopes for patients to have a treatment option for neuropathic pain as a non-opioid. Secondly, it proves how safe AV-101 is as a drug. In my opinion, the good part about having such a safe drug is the ability to be able to raise the dose levels if necessary. That in turn could potentially improve efficacy outcome for newer clinical trials.

Current Antidepressants

The biggest problem with relying on current antidepressants is that they have a lot of unwanted side effects. Such side effects include: Weight gain, nausea, decreased libido, anxiety, and many others. AV-101 has been safe and does not have such terrible side effects. The current drugs can take up to 8 weeks or more to start working in MDD patients, time that these patients can’t afford to lose.  The final factor is that 1 in 3 MDD patients who take current antidepressants don’t respond to treatment.

View single page >> |

Disclosure: This article is part of a new “UnderCovered” series of exclusive articles featuring companies with limited coverage. Authors are compensated by TalkMarkets for their time, and ...

more
How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.
Paul B 3 years ago Member's comment

When I say I was in a different place that was when the drug was intravenous but until Wednesday very good. Regards Paul

Ayelet Wolf 3 years ago Member's comment

Thanks for sharing but I'm not clear what your point is Paul.

Paul B 3 years ago Member's comment

I suffer from MDD and was admitted to a psychiatric hospital.There are two hospitals in the UK and they are testing ketamine. One is Oxford and the other One is Northampton.The Dr ask me if I would be willing to take part in the test and when you suffered with depression for many years you would do anything to get out of the big black cloud that makes life unbearable.it was amazing it was like you were in a different place,so relaxing.The trials were every Friday you would document everyday on your computer.For me it was very effective but I noted it would last until Wednesday obviously this is a trial and as time when by they would now what dose you would require.But unfortunately I was taken of the test because I was on a very strong opioid and obviously they were testing a new drug and could not take any chances as it did not have a license. Regards Paul

Derek Snyder 3 years ago Member's comment

Your argument for acquisition sounds convincing, but I wonder if there have been any such overtures. Know if that's the case? Which companies would be the most likely to target #Vistagen? $VTGN.

David M. Green 3 years ago Member's comment

Looks promising. Sounds like $VTGN should be getting more love from investors.

Bill Johnson 3 years ago Member's comment

Definitely sounds like some interesting prospects indeed! $VTGN

Alexis Renault 3 years ago Member's comment

Thanks Terry Chrisomalis, can you explain what a "first-line, second-line, and third-line of treatment" is?

Terry Chrisomalis 3 years ago Author's comment

That is taking one SSRI drug for 4-8 weeks then it not working, then taking another SSRI drug for 4-8 weeks and it not working etc. Then eventually following up with adding atypical antipsychotics

Alexis Renault 3 years ago Member's comment

Thanks Terry! Will take a closer look at $VTGN.